Evidence map›Paper›PMID 31717403›Full record

ArticleInternational journal of molecular sciences2019

Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.

József Murányi, Attila Varga, Pál Gyulavári, Kinga Pénzes, Csilla E Németh, Miklós Csala, Lilla Pethő, Antal Csámpai, Gábor Halmos, István Peták and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Frontiers in endocrinology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

József MurányiMTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.ORCID 0000-0001-5672-6482
Attila VargaMTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Pál GyulaváriMTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Kinga PénzesMTA-SE Pathobiochemistry Research Group, Tűzoltó St. 37-47, H1094 Budapest, Hungary.
Csilla E NémethDepartment of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H1094 Budapest, Hungary.
Miklós CsalaDepartment of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, H1094 Budapest, Hungary.ORCID 0000-0002-3829-4361
Lilla PethőMTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, H1117 Budapest, Hungary.ORCID 0000-0002-0298-3341
Antal CsámpaiInstitute of Chemistry, Eötvös Loránd University, H1117 Budapest, Hungary.
Gábor HalmosDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, H4032 Debrecen, Hungary.
István PetákOncompass Medicine Hungary Ltd., H1024 Budapest, Hungary.
István Vályi-NagyCentral Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, H1097 Budapest, Hungary.
Semmelweis University · HUEötvös Loránd University · HUNational Center for Epidemiology · HUUniversity of Debrecen · HU

Funding

Emberi Eroforrások Minisztériuma 20428-3/2018/FEKUTSTRATNemzeti Kutatási, Fejlesztési és Innovaciós Alap GINOP-2.3.2-15-2016-00043Nemzeti Kutatási, Fejlesztési és Innovaciós Alap "K-124813Nemzeti Kutatási, Fejlesztési és Innovaciós Alap K-128785Nemzeti Kutatási, Fejlesztési és Innovaciós Alap NVKP_16-1-2016-0005
6 · The paper itself

Abstract

Several promising anti-cancer drug-GnRH (gonadotropin-releasing hormone) conjugates have been developed in the last two decades, although none of them have been approved for clinical use yet. Crizotinib is an effective multi-target kinase inhibitor, approved against anaplastic lymphoma kinase (ALK)- or ROS proto-oncogene 1 (ROS-1)-positive non-small cell lung carcinoma (NSCLC); however, its application is accompanied by serious side effects. In order to deliver crizotinib selectively into the tumor cells, we synthesized novel crizotinib analogues and conjugated them to a [d-Lys

Indexed as

Drug Delivery SystemsCarcinoma, Non-Small-Cell LungCell Line, TumorCell Membrane PermeabilityCell SurvivalCrizotinibDrug DesignFibroblastsGalectinsGonadotropin-Releasing HormoneHumansHydrogen-Ion ConcentrationLung NeoplasmsLysosomesModels, BiologicalProto-Oncogene MasCrizotinibGalectinsGonadotropin-Releasing HormoneMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins c-metReceptors, LHRHc-Met 8conjugate 6crizotinib 5endocytosis 9galectin 10GnRH 2GnRHR 3lysosome 3NSCLC 7permeability 4targeted drug delivery 1

Identifiers

PMID31717403
PMCPMC6888004
OpenAlexW2986408923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.